Search

News Long-term effect of the triple combination of perindopril, indapamide, and amlodipine on left ventricular hypertrophy in hypertension

A recent open-label interventional study aimed to describe the long-term effect of a fixed triple combination of perindopril, indapamide, and amlodipine compared to a free combination of a RAAS inhibitor, diuretic, and calcium channel blocker on the reduction of left ventricular hypertrophy (LVH) in hypertensive outpatients.

Source: ACE inhibitory 18. 4. 2021

News What is the Impact of Bisoprolol on Plasma Concentrations of Dabigatran

Many patients on anticoagulant therapy with dabigatran also use the beta-blocker bisoprolol. The Slovak prospective observational study was based on the assumption that bisoprolol, as a significant inhibitor of P-glycoprotein, may interact with dabigatran and focused on examining the effect of this beta-blocker on plasma concentrations of dabigatran.

Source: Cardiovascular Continuum 16. 9. 2022

News Targeted Treatment of Children and Adolescents with Severe AD –⁠ Case Studies

The results of therapy with dupilumab in children and adolescents with severe forms of atopic dermatitis (AD) are very good even after a short period, not only from a health perspective but also in terms of the social aspect of the disease and the quality of life of patients. This is illustrated by the following two case studies –⁠ an 8-year-old girl and a 17-year-old boy –⁠ from the Center for Biological Treatment at the Dermatovenerology Clinic of the 2nd Faculty of Medicine, Charles University, and Bulovka University Hospital.

Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 2. 3. 2023

News Dual Inhibition of IL-17A/IL-17F Across the Spectrum of Axial Spondyloarthritis

Many patients with axial spondyloarthritis (axSpA) still have a need to seek additional therapeutic options and new mechanisms of action for medicinal substances. Phase III studies BE MOBILE 1 and 2 therefore evaluated the effect of administering bimekizumab—a monoclonal antibody selectively inhibiting interleukins (IL) 17A and 17F—across the full spectrum of patients with axSpA.

Source: Rheumatic Diseases 1. 12. 2023

News Safety and Efficacy of Long-term Tofacitinib Therapy in Patients with Active Psoriatic Arthritis –⁠ Interim Results of the OPAL Balance Study

Tofacitinib is a potent selective inhibitor of the Janus kinase (JAK) family indicated for the treatment of active psoriatic arthritis in adult patients. The efficacy and safety of tofacitinib in this population have been verified for 6 and 12 months through clinical studies OPAL. A study published in 2020 presents interim results of the extended phase of these studies, evaluating its efficacy and safety in the long term.

Source: Arthritis 30. 5. 2022

News Improvement of Joint and Skin Symptoms and Their Contribution to Improving the Quality of Life in Patients with Psoriatic Arthritis

The cause of reduced quality of life in patients with psoriatic arthritis is the involvement of both skin and joints. Commonly used therapy certainly improves symptoms of both systems to some extent, but to what extent does this improvement correlate with a higher health-related quality of life? This question was addressed by analyzing two randomized studies.

Source: Biological Treatment 21. 8. 2020

News Venetoclax in the Treatment of CLL: Open Doors for the Longest Possible Maintenance of Remission Without Active Therapy

William G. Wierda from MD Anderson Cancer Center in Houston, USA, and Francesco P. Tambaro from Azienda Ospedaliera di Rilievo Nazionale Santobono-Pausilipon in Naples, Italy, evaluate in their report for the journal Blood from April 2020 the practical aspects and benefits of using venetoclax in the first-line treatment of chronic lymphocytic leukemia (CLL), as well as in cases of relapsing/refractory forms of the disease.

Source: Chronic Lymphocytic Leukemia 8. 6. 2020

News An Introductory Word to the Section on Hereditary Angioedema —⁠ MUDr. Roman Hakl, Ph.D.

Hereditary angioedema (HAE) is a genetically conditioned disease, currently classified into HAE with C1 inhibitor deficiency (HAE-C1-INH), referred to as HAE-I and HAE-II, and HAE with normal level and function of C1 inhibitor (HAE nC1-INH), also referred to as HAE-III (1).

Source: Hereditary Angioedema 29. 7. 2020

News Reduction of Risk of Hospitalizations for Heart Failure in Type 2 Diabetics

The EMPA-REG OUTCOME study already in 2015 highlighted one of the benefits of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin, which is the reduction of the risk of hospitalization for heart failure in patients with type 2 diabetes mellitus (T2DM) with high cardiovascular (CV) risk. Compared to placebo, empagliflozin reduced this risk by a relative 35%.

Source: Heart Failure 2. 12. 2021

News How to Communicate and Receive an Oncological Diagnosis

Communicating the truth to a patient about their health condition does not have a very long tradition in the Czech Republic. The Czech healthcare system started emphasizing this aspect, i.e., honest and open communication between doctor and patient, several years after the Velvet Revolution.

Source: Ovarian and Breast Cancer 4. 6. 2020

News Tofacitinib in the Treatment of Ulcerative Colitis in Real-World Practice in the USA

A recently published study summarizes the characteristics of patients newly treated with tofacitinib for ulcerative colitis (UC), the impact of initiating tofacitinib on corticosteroid use, and adherence to this treatment in real-world practice based on a retrospective analysis of data from a large health database in the USA.

Source: Intestinal Inflammations 22. 6. 2023

News Tofacitinib Through the Eyes of Patients: Rapid Response After Treatment Initiation

How does tofacitinib fare in the treatment of ulcerative colitis in real clinical practice from the patients' perspective? This was addressed in a recent study published in the journal Inflammatory Bowel Diseases.

Source: Intestinal Inflammations 5. 7. 2023

News New scoring system for predicting long-term survival of AML patients over 70 years and suitable for intensive chemotherapy

Based on the analysis of data from 3 large European registries (DATAML, SAL, and PETHEMA), a prognostic score for 5-year survival was created and validated for patients with acute myeloid leukemia (AML) who were given intensive chemotherapy. The ESS70+ score, determined based on parameters known at the time of diagnosis, is easily usable in routine practice for estimating overall survival of older AML patients and facilitates decisions about intensive chemotherapy.

Source: Acute Myeloid Leukemia 10. 5. 2024

News Correlation of Levothyroxine Dose with Autoimmune Antibody Titer in Primary Hypothyroidism

The relationship between the level of antithyroid antibodies and the required dose of levothyroxine in substitution for autoimmune hypothyroidism is a poorly explored question. Therefore, a retrospective study of more than 300 patients was conducted, and we bring you a brief summary.

Source: Thyroid Disorders 14. 9. 2022

News Effect of Cataract Surgery on Melatonin Secretion in Adults Aged 60 and Over

A study by ophthalmologists and epidemiologists from Nara University in Japan, recently published in JAMA Ophthalmology, examined the relationship between cataract surgery, the use of clear and yellow intraocular lenses, and the level of melatonin secretion.

Source: Glaucoma 8. 6. 2020